TARGETED ONCOLOGY THERAPEUTICS
Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products against non-functional P2X7 (nfP2X7), a cancer target that has been shown to be present on the majority of cancers. Our goal is to bring novel therapeutics to patients suffering from a wide range of malignancies.
CAR-T CELL THERAPY
Our lead program is an nfP2X7 targeted chimeric antigen receptor T-cell (CAR-T) therapeutic for haematological malignancies, combining the exquisite specificity of our proprietary nfP2X7-targeting antibodies with the patient’s own immune cells to deliver a product that we believe has the potential to benefit a great number of cancer patients with limited other treatment options.
As we build our organisation into the future, we will seek to exploit the modular nature of our nfP2X7 technology to expand our pipeline with a range of therapeutic formats, including CAR-T for solid tumours, monoclonal antibodies, bi-specific antibodies and antibody-drug conjugates, where these modalities may provide an advantage for specific populations of cancer patients.
We continue to source and partner with world class talent to ensure we can deliver on the promise of our novel technology.